Eversense CGM
Evaluate the effectiveness of diabetes management with Eversense CGM system non-adjunctively compared to self-monitoring of blood glucose (SMBG) using a blood glucose (BG) meter in participants with either Type 1 or type 2 diabetes.
Evaluate the effectiveness of diabetes management with Eversense CGM system non-adjunctively compared to self-monitoring of blood glucose (SMBG) using a blood glucose (BG) meter in participants with either Type 1 or type 2 diabetes.
This is a randomized, double-blind, parallel group clinical study designed to evaluate the safety and efficacy of ricolinostat for painful diabetic neuropathy.
The Protect study will determine whether teplizumab slows the loss of β cells and preserves β cell function in children and adolescent 8-17 years old who have been diagnosed with T1D in the previous 6 weeks.
The purpose of this study is to measure how well LY3819253 and LY3832479 work against the virus that causes COVID-19. LY3819253 and LY3832479 will be given to participants with early symptoms of COVID-19, via an injection into a vein. Samples will be taken from the back of the nose to determine how much virus is […]
The BDCP clinical study is for type 1 diabetes patients, 18 years or older, to evaluate the safety of LY3209590 in patients being treated with multiple daily injection therapy.
Fill out the form below an we will let you know when a study becomes available that you may be interested in: